#fda-approval

#fda-approval

"Waist circumference, blood pressure, LDL cholesterol, resting heart rate - they are much better measures of how healthy someone is than glucose," the University of Oxford's Nicola Guess told The Atlantic.

Wildtype's salmon is not a plant-based meat alternative; it's actual salmon, derived from Pacific salmon cells that have been fed with nutrients like protein, fat, and salt.

The approval of lenacapavir, requiring a twice-yearly injection, represents a significant leap in HIV prevention efforts, especially improving compliance over daily pill regimens.

"Even a single FMT will cause a change in the host-microbe relationships in these very different regions of the bowel that may be very difficult to reverse."

Butterfly pea flower extract, used for centuries in various cultures for its vibrant color, has been approved by the FDA as a natural food coloring option.

It is estimated that 700,000 Americans are currently afflicted with alopecia areata, with rates higher in minority communities, showcasing the urgent need for effective treatments.

"The pain always travels in some way, and it's undeniably overwhelming," explained Terri Battenburg. "I usually just try to power through it, but it's like trying to swim through mud."

With full FDA approval, Novavax would have permission to keep its shot on the market indefinitely, as emergency authorization can be revoked after a health emergency.

Sanofi and Alnylam's fitusiran (Qfitlia) is a groundbreaking treatment approved by the FDA for routine prophylaxis in patients with hemophilia A or B, distinguishing itself with a dosing schedule of once every two months.

The tragic death of a patient on Sarepta's Elevidys highlights the urgent need for continued monitoring and research into the long-term safety of gene therapies.

The common law experimental use exemption particularly narrows patent infringement protections, applying only to non-commercial, purely experimental uses, posing significant risks for researchers.

Bluebird Bio, a company that steered three gene therapies to FDA approval but struggled to commercialize them, has found the cash it needs to put those therapies on stronger financial footing by reaching a deal to sell itself to two private equity firms for about $29 million.